-
公开(公告)号：EP1718678B1
公开(公告)日：2017-10-11
申请号：EP05718988.8
申请日：2005-02-16
发明人： DE SANTIS, Rita, Sigma-Tau Industrie , PELLICCIA, Angela, Sigma-Tau Industrie , PALOMBO, Giovanna , CARMINATI, Paolo, Sigma-Tau Industrie
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/18 , C07K2317/56 , C07K2317/92 , Y10S435/81
-
公开(公告)号：EP2842557A1
公开(公告)日：2015-03-04
申请号：EP13182338.7
申请日：2013-08-30
发明人： Pescosolido, Nicola
IPC分类号： A61K31/205 , A61P27/02 , A61P27/06
CPC分类号： A61K31/205
摘要： The present invention relates to mildronate for use in the prevention or treatment of ophthalmic disorders associated with an abnormal cell proliferation and/or ocular neovascularization, such as for example neovascular glaucoma, and/or proliferative vitreoretinopathy. The administration is preferably by intravitreal injection.
摘要翻译： 本发明涉及用于预防或治疗与异常细胞增殖和/或眼新生血管形成（例如新生血管性青光眼）和/或增殖性玻璃体视网膜病变有关的眼科疾病的氟磷酸盐。 给药优选通过玻璃体内注射。
-
-
4.发明公开COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENT L-CARNITINE OR PROPIONYL L-CARNITINE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY 有权L-肉碱或Proponyl-L-肉碱的组合的组合物作为用于慢性静脉功能不全的预防或治疗剂
公开(公告)号：EP2531189A1
公开(公告)日：2012-12-12
申请号：EP11709464.9
申请日：2011-02-07
IPC分类号： A61K31/205 , A61K31/7048 , A61P9/14
CPC分类号： A61K31/7048 , A61K31/205 , A61K31/221 , A61K45/06 , A61K2300/00
摘要： It is described a combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and /or treatment of chronic venous diseases.
-
5.发明授权CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM 有权7-（二甲氧基甲基）晶型II的 - 喜树碱和中间体USE THEREOF，与产品获得
公开(公告)号：EP2170900B1
公开(公告)日：2012-12-12
申请号：EP08786333.8
申请日：2008-07-22
发明人： CABRI, Walter , MARZI, Mauro , GIORGI, Fabrizio , BADALONI, Elena , ARMAROLI, Silvia , MARAZZI, Giuseppe
IPC分类号： C07D491/22
CPC分类号： C07D491/22
-
6.发明授权A MEDICAMENT FOR THE TWO-STEP PERIOPERATIVE THERAPY OF SOLID TUMOURS BY RADIOIMMUNOTHERAPY 有权药物通过无线电免疫疗法二段围手术期治疗实体瘤
公开(公告)号：EP1615668B1
公开(公告)日：2012-12-05
申请号：EP04726249.8
申请日：2004-04-07
发明人： PAGANELLI, Giovanni, c/oSigma-Tau , CARMINATI, Paolo, c/o Sigma-Tau , VERONESI, Umberto, c/o Sigma-Tau
IPC分类号： A61K47/48 , A61K39/395 , A61K31/4188 , A61K51/00 , A61P35/00
CPC分类号： B82Y5/00 , A61K31/4188 , A61K47/6898 , A61K51/1093
-
7.发明公开ANTICANCER COMBINATION OF ARTEMISININ-BASED DRUGS AND OTHER CHEMOTHERAPEUTIC AGENTS 审中-公开作者基于青蒿素的活性物质UDN其它化疗抗癌组合
公开(公告)号：EP2515898A1
公开(公告)日：2012-10-31
申请号：EP10788312.6
申请日：2010-12-06
发明人： PISANO, Claudio , VESCI, Loredana
IPC分类号： A61K31/24 , A61K31/335 , A61K31/4745 , A61K31/704 , A61P35/00
CPC分类号： A61K31/24 , A61K31/335 , A61K31/4745 , A61K31/704 , A61K2300/00
摘要： The present invention relates to combinations between artemisinin-based potent anti-malarial agents, selected from the group consisting of ART, DHA and ARM, and a further chemotherapeutic drug selected from the group consisting of a camptothecin derivative, or a PARP-1 inhibitor, or an intercalating DNA agent, or an alkylating agent. Such combinations, showed medium to strong synergism in various models of cancer, in particular in NSCL.
-
公开(公告)号：EP1828196B1
公开(公告)日：2012-10-17
申请号：EP05849781.9
申请日：2005-12-16
发明人： CARMINATI, Paolo , TINTI, Maria Ornella , MARZI, Mauro , GIORGI, Fabrizio , CABRI, Walter , ALPEGIANI, Marco , VERGANI, Domenico , GHETTI, Paolo
IPC分类号： C07D491/22
CPC分类号： C07D491/22
-
9.发明授权USE OF THYMOSIN 1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION 有权USE胸腺素1; 单独或与PTX3或更昔洛韦联合用于治疗巨细胞病毒感染
公开(公告)号：EP2012816B1
公开(公告)日：2012-06-27
申请号：EP07728041.0
申请日：2007-04-12
IPC分类号： A61K38/22
CPC分类号： A61K38/1709 , A61K31/522 , A61K38/2292 , A61K2300/00
摘要： It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation.
-
10.发明公开OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS 有权作为配体腺苷A2A受体有用TRIAZOLYLPURINEN被氧化的衍生物，以及它们的用途，药物
公开(公告)号：EP2408775A1
公开(公告)日：2012-01-25
申请号：EP10709526.7
申请日：2010-03-18
IPC分类号： C07D473/34 , A61K31/52 , A61P25/00 , A61P25/16 , A61P25/28
CPC分类号： C07D473/34 , A61K31/198 , A61K31/52
摘要： The present invention relates to new triazolyl purine derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders or cerebral ischaemia for which inhibition of adenosine A2A receptor will result at improving the health state of a patient.
-
-
-
-
-
-
-
-
-
搜索结果
577 条记录 (耗时 0.023 秒)
